BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology 2015;95:121-9. [PMID: 25749357 DOI: 10.1016/j.neuropharm.2015.02.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Naren P, Cholkar A, Kamble S, Samim KS, Srivastava S, Madan J, Mehra N, Tiwari V, Singh SB, Khatri DK. Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay. JAD 2022. [DOI: 10.3233/jad-220682] [Reference Citation Analysis]
2 Calabrese V, Picconi B, Heck N, Campanelli F, Natale G, Marino G, Sciaccaluga M, Ghiglieri V, Tozzi A, Anceaume E, Cuoc E, Caboche J, Conquet F, Calabresi P, Charvin D. A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109205] [Reference Citation Analysis]
3 Frouni I, Huot P. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic. Neurodegenerative Disease Management. [DOI: 10.2217/nmt-2021-0055] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bandopadhyay R, Mishra N, Rana R, Kaur G, Ghoneim MM, Alshehri S, Mustafa G, Ahmad J, Alhakamy NA, Mishra A. Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence. Front Pharmacol 2022;13:805388. [DOI: 10.3389/fphar.2022.805388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Angela Cenci M, Skovgård K, Odin P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mann E, Jackson M, Lincoln L, Fisher R, Rose S, Duty S. Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets. J Parkinsons Dis 2020;10:959-67. [PMID: 32250315 DOI: 10.3233/JPD-191824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Vidal B, Levigoureux E, Chaib S, Bouillot C, Billard T, Newman-tancredi A, Zimmer L. Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson’s Disease and Levodopa-Induced Dyskinesia: A MicroPET Study. JPD 2021;11:1257-69. [DOI: 10.3233/jpd-212580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zheng C, Zhang F. New insights into pathogenesis of l-DOPA-induced dyskinesia. Neurotoxicology 2021;86:104-13. [PMID: 34331976 DOI: 10.1016/j.neuro.2021.07.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Waku I, Magalhães MS, Alves CO, de Oliveira AR. Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies. Eur J Neurosci 2021;53:3743-67. [PMID: 33818841 DOI: 10.1111/ejn.15222] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Gregory KJ, Goudet C. International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors. Pharmacol Rev 2021;73:521-69. [PMID: 33361406 DOI: 10.1124/pr.119.019133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
11 Doller D, Bespalov A, Miller R, Pietraszek M, Kalinichev M. A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson's disease: translational gaps or a failing industry innovation model? Expert Opin Investig Drugs 2020;29:1323-38. [PMID: 33074728 DOI: 10.1080/13543784.2020.1839047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
12 Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH. Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update. CNS Drugs 2020;34:1025-44. [PMID: 32785890 DOI: 10.1007/s40263-020-00754-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
13 Zhang Z, Zhang S, Fu P, Zhang Z, Lin K, Ko JK, Yung KK. Roles of Glutamate Receptors in Parkinson's Disease. Int J Mol Sci 2019;20:E4391. [PMID: 31500132 DOI: 10.3390/ijms20184391] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
14 Del Bello F, Giannella M, Giorgioni G, Piergentili A, Quaglia W. Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. Biomolecules 2019;9:E142. [PMID: 30970612 DOI: 10.3390/biom9040142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
15 Xu Y, Li Z. Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development. Med Res Rev 2019;39:1892-922. [DOI: 10.1002/med.21566] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
16 Crupi R, Impellizzeri D, Cuzzocrea S. Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front Mol Neurosci 2019;12:20. [PMID: 30800054 DOI: 10.3389/fnmol.2019.00020] [Cited by in Crossref: 55] [Cited by in F6Publishing: 73] [Article Influence: 18.3] [Reference Citation Analysis]
17 Dragašević-Mišković N, Petrović I, Stanković I, Kostić VS. Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients. Expert Opin Pharmacother 2019;20:219-30. [PMID: 30411647 DOI: 10.1080/14656566.2018.1543407] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Du JJ, Chen SD. Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease. Chin Med J (Engl) 2017;130:1856-66. [PMID: 28748860 DOI: 10.4103/0366-6999.211555] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
19 Charvin D. mGlu4 allosteric modulation for treating Parkinson's disease. Neuropharmacology 2018;135:308-15. [PMID: 29578036 DOI: 10.1016/j.neuropharm.2018.03.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
20 Sebastianutto I, Cenci MA. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia. Current Opinion in Pharmacology 2018;38:81-9. [DOI: 10.1016/j.coph.2018.03.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
21 Mellone M, Gardoni F. Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications. J Neural Transm 2018;125:1225-36. [DOI: 10.1007/s00702-018-1846-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
22 Peska L, Buza K, Koller J. Drug-target interaction prediction: A Bayesian ranking approach. Computer Methods and Programs in Biomedicine 2017;152:15-21. [DOI: 10.1016/j.cmpb.2017.09.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
23 Quiroga-Varela A, Aguilar E, Iglesias E, Obeso JA, Marin C. Short- and long-term effects induced by repeated 6-OHDA intraventricular administration: A new progressive and bilateral rodent model of Parkinson's disease. Neuroscience 2017;361:144-56. [PMID: 28823819 DOI: 10.1016/j.neuroscience.2017.08.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
24 Chotibut T, Meadows S, Kasanga EA, McInnis T, Cantu MA, Bishop C, Salvatore MF. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model. Mov Disord 2017;32:1547-56. [PMID: 28631864 DOI: 10.1002/mds.27077] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
25 Ribeiro FM, Vieira LB, Pires RG, Olmo RP, Ferguson SS. Metabotropic glutamate receptors and neurodegenerative diseases. Pharmacological Research 2017;115:179-91. [DOI: 10.1016/j.phrs.2016.11.013] [Cited by in Crossref: 105] [Cited by in F6Publishing: 120] [Article Influence: 21.0] [Reference Citation Analysis]
26 Sebastianutto I, Maslava N, Hopkins CR, Cenci MA. Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. Neurobiol Dis 2016;96:156-70. [PMID: 27597526 DOI: 10.1016/j.nbd.2016.09.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
27 Bruno V, Caraci F, Copani A, Matrisciano F, Nicoletti F, Battaglia G. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders. Neuropharmacology 2017;115:180-92. [PMID: 27140693 DOI: 10.1016/j.neuropharm.2016.04.044] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
28 Litim N, Morissette M, Di Paolo T. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research. Neuropharmacology 2017;115:166-79. [PMID: 27055772 DOI: 10.1016/j.neuropharm.2016.03.036] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 8.2] [Reference Citation Analysis]
29 Asakawa T, Fang H, Sugiyama K, Nozaki T, Hong Z, Yang Y, Hua F, Ding G, Chao D, Fenoy AJ, Villarreal SJ, Onoe H, Suzuki K, Mori N, Namba H, Xia Y. Animal behavioral assessments in current research of Parkinson's disease. Neurosci Biobehav Rev 2016;65:63-94. [PMID: 27026638 DOI: 10.1016/j.neubiorev.2016.03.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
30 Bouillot C, Bonnefoi F, Liger F, Zimmer L. A microPET comparison of the effects of etifoxine and diazepam on [ 11 C]flumazenil uptake in rat brains. Neuroscience Letters 2016;612:74-9. [DOI: 10.1016/j.neulet.2015.11.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
31 Kil KE, Poutiainen P, Zhang Z, Zhu A, Kuruppu D, Prabhakar S, Choi JK, Tannous BA, Brownell AL. Synthesis and evaluation of N-(methylthiophenyl)picolinamide derivatives as PET radioligands for metabotropic glutamate receptor subtype 4. Bioorg Med Chem Lett 2016;26:133-9. [PMID: 26602273 DOI: 10.1016/j.bmcl.2015.11.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
32 Garcia-Barrantes PM, Cho HP, Niswender CM, Byers FW, Locuson CW, Blobaum AL, Xiang Z, Rook JM, Conn PJ, Lindsley CW. Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics. J Med Chem 2015;58:7959-71. [PMID: 26426481 DOI: 10.1021/acs.jmedchem.5b00727] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
33 Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdère P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bézard E. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 2015;132:96-168. [PMID: 26209473 DOI: 10.1016/j.pneurobio.2015.07.002] [Cited by in Crossref: 254] [Cited by in F6Publishing: 258] [Article Influence: 36.3] [Reference Citation Analysis]
34 Zhang Z, Kil KE, Poutiainen P, Choi JK, Kang HJ, Huang XP, Roth BL, Brownell AL. Re-exploring the N-phenylpicolinamide derivatives to develop mGlu4 ligands with improved affinity and in vitro microsomal stability. Bioorg Med Chem Lett 2015;25:3956-60. [PMID: 26231155 DOI: 10.1016/j.bmcl.2015.07.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]